|
|
Article: FDA Clears MBL Bullous Pemphigoid ELISA Test.
- Article from:
- Biotech Week
- Article date:
- October 8, 2008
CopyrightCOPYRIGHT 2008 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
MBL International Corporation of Woburn, Massachusetts is announcing that the United States Food and Drug Administration, FDA, has cleared the BP180 and BP230 ELISA Kits for the detection of Bullous Pemphigoid (BP), the new kits have been CE marked as well. The new kits are seen as an advance in diagnosing Bullous Pemphigoid (see also Bullous Pemphigoid).
MBLI's Chief Executive Officer Dennis Walczewski, was pleased to offer this new medical advance and was quoted as saying, "These new kits present a significant advance in testing for this irritating skin malady and it is our hope that improved testing can lead to better treatment."
Bullous Pemphigoid, ...